
Auricle
Auricle is a YC Winter 2021 (W21) company. Based in Mountain View, CA, USA; Oakland, CA, USA. Team of 2.
About Auricle
Summary
Auricle builds a neurostimulation implant for patients with severe high-frequency hearing loss who get limited benefit from hearing aids but have not pursued a cochlear implant, often because of the risk of losing remaining natural hearing. The device electrically stimulates auditory neurons through a reversible, less invasive procedure that preserves residual hearing, filling the treatment gap between hearing aids and cochlear implants. It replaces a clinical dead end where no approved device currently exists for this patient profile.
Go-to-market
Auricle targets patients diagnosed with severe-to-profound high-frequency hearing loss through the medical device regulatory and clinical trial pathway, working toward a first-in-human implant trial before commercial rollout.
From the Y Combinator listing
Neurostimulation implant to restore hearing & speech understanding
Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.
Facts
- Healthcare / Healthcare -> Medical Devices
- Mountain View, CA, USA; Oakland, CA, USA
- 2
- Active
- Early
Founders (2)
- Jay Dhuldhoya
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works